Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cell-Therapy Deals A "Strategic Priority" For Shire

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire seeks to build on its May 2011 acquisition of Advanced BioHealing with further cell-therapy deals.
Advertisement

Related Content

Juventas Moves Into Phase II With Funds From $22M Series B
Pervasis Buyout Increases Shire’s Expertise In Regenerative Medicine
Promethera's Cell Therapy Attracts Corporate VCs To Largest European Biopharma Funding Round This Year
Time To Strike On Regenerative Medicine/Stem Cell Companies?
Disappointing Provenge Sales Stir Doubts About Demand
Advanced BioHealing To Bring Regeneration To Shire
Advanced BioHealing To Bring Regeneration To Shire
U.K. Biotech Renovo's Future On The Line As Phase III Lead Crashes
Shire/TKT: The Price of Diversification
Shire/TKT: The Price of Diversification

Topics

Advertisement
UsernamePublicRestriction

Register

PS072744

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel